Karyopharm Therapeutics (NASDAQ:KPTI) vs. Hikma Pharmaceuticals (OTCMKTS:HKMPF) Critical Contrast

Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Karyopharm Therapeutics (NASDAQ:KPTI) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Profitability

This table compares Hikma Pharmaceuticals and Karyopharm Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	N/A	N/A	N/A
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Risk & Volatility

Hikma Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Valuation & Earnings

This table compares Hikma Pharmaceuticals and Karyopharm Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	$3.35 billion	1.35	$402.00 million	N/A	N/A
Karyopharm Therapeutics	$151.12 million	1.12	-$196.04 million	($15.09)	-0.50

Hikma Pharmaceuticals has higher revenue and earnings than Karyopharm Therapeutics.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Hikma Pharmaceuticals and Karyopharm Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	1	0	1	0	2.00
Karyopharm Therapeutics	1	0	5	1	2.86

Karyopharm Therapeutics has a consensus price target of $17.17, suggesting a potential upside of 129.81%. Given Karyopharm Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Hikma Pharmaceuticals.

Insider & Institutional Ownership

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Hikma Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.